CommercialPrior AuthLow impact
Elivaldogene Autotemcel (Skysona®)
BCBS Tennessee·TN · Pediatrics, Neurology, Oncology +1 more·Medical Policy
Effective date
Jul 31, 2026
We identified it
Jun 17, 2026
Summary
BlueCross BlueShield of Tennessee is implementing a new medical policy for Elivaldogene Autotemcel (Skysona®), a gene therapy for boys aged 4-17 with early, active cerebral adrenoleukodystrophy (CALD). The policy establishes extensive prior authorization requirements and coverage criteria for this specialized treatment.
Action Required
Before July 31, 2026: Review and understand the new Skysona® policy requirements. If your practice treats pediatric patients with adrenoleukodystrophy, establish workflows for prior authorization documentation including genetic testing results, MRI findings, lab values, and specialist consultation requirements. Update prior auth checklists to include the extensive clinical criteria.